License Our Molecules

Request edit access

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Profluent's foundation models enable us to design all of life's large molecules. We have a growing list of molecular assets available for partners. For example, partners are exploring using our validated epitope-specific antibodies for bispecifics and our gene editors for therapeutics.

Our assets can be easily licensed, with flexible economics -- some even royalty-free or without upfront fees.

Have a specific customized request? We also work with partners on bespoke protein design solutions. Fill out the form to start the conversation!

Company or Organization Name *

Company Type *

Startup (<50 employees)

Growth-stage company (50-500 employees)

Large company (>500 employees)

Academic / Non-profit

Other:

Your Name *

Your Role or Department

Business Email Address *

Country *

Which antibody asset(s) are you interested in?

unique antibody targeting the exact PD1 epitope as pembrolizumab

unique antibody targeting the exact PD1 epitope as nivolumab

unique antibody targeting the exact PD1 epitope as serplulimab

unique antibody targeting the exact CD124 epitope as dupilumab

unique antibody targeting the exact CD152 epitope as ipilimumab

unique antibody targeting the exact CD20 epitope as ofatumumab

unique antibody targeting the exact CD20 epitope as obinutuzumab

unique antibody targeting the exact CD38 epitope as daratumumab

unique antibody targeting the exact CD38 epitope as isatuximab

unique antibody targeting the exact plasma kallikrein epitope as lanadelumab

unique antibody targeting the exact BAFF epitope as belimumab

unique antibody targeting the exact CD274 epitope as durvalumab

unique antibody targeting the exact CD274 epitope as atezolizumab

unique antibody targeting the exact EGFR epitope as necitumumab

unique antibody targeting the exact IL1B epitope as canakinumab

unique antibody targeting the exact IL6 epitope as olokizumab

unique antibody targeting the exact LFA1A epitope as efalizumab

unique antibody targeting the exact TNFA epitope as adalimumab

unique antibody targeting the exact TNFA epitope as infliximab

unique antibody targeting the exact VEGFR2 epitope as ramucirumab

Other:

Which gene editing or enzyme asset(s) are you interested in?

novel deaminase for base editing

novel nickase (less than 1000 amino acid length)

programmable DNA binder for epigenetic editing (less than 600 amino acid length)

nuclease with a custom PAM

compact reverse transcriptase (smaller than MMLV RT)

Other:

What is your desired *minimum* data package for experimental validation of the discovery-stage asset(s) above before you would consider licensing? *

What is the general field you're interested in using this asset for? *

Human Therapeutics

Diagnostics

Agriculture

Biomanufacturing

Other:

Required

Which scenario describes your ideal license economics? *

No upfront fee, bias towards downstream economics (milestones/royalties)

Upfront fee and milestones, no royalties

Middle of the road across all near- and long-term economics

Other:

Have a custom request within antibodies, gene editing, or enzymes? Let us know and we can work on a bespoke solution together.

Submit

Clear form

Never submit passwords through Google Forms.

This form was created inside of Profluent Bio.

Does this form look suspicious? Report

Forms